Omega Diagnostics Group PLC (LON:ODX) target price held steady at 28.00GBX, reported today by finnCap
- Updated: November 29, 2016
Omega Diagnostics Group PLC (LON:ODX) had its target price hold steady to 28.00GBX by finnCap in a report released 11/29/2016. The new target price indicates a possible upside of 0.51% based on the company's last stock close price.
Previously on 11/21/2016, finnCap reported about Omega Diagnostics Group PLC (LON:ODX) held steady the target price at 28.00GBX. At the time, this indicated a possible upside of 0.59%.
Yesterday Omega Diagnostics Group PLC (LON:ODX) traded -2.03% lower at 18.50GBX. The company’s 50-day moving average is 17.37GBX and its 200-day moving average is 17.23GBX. The last stock close price is up 5.17% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 38,629 shares of the stock were exchanged, down from an average trading volume of 72,503
See Chart Below
Omega Diagnostics Group PLC has a 52 week low of 13.50GBX and a 52 week high of 21.00GBX with a P/E ratio of 36.25 The company’s market cap is currently 0 GBX.
In addition to finnCap reporting its target price, a total of 1 firm has reported on the stock. The consensus target price is 28.00GBX with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Omega Diagnostics Group PLC (LON:ODX)
Omega Diagnostics Group PLC is a medical diagnostics company. The Company's segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers. For allergy, it offers Allergodip, which is an enzyme immunoassay for the semi-quantitative determination of Specific immunoglobulin E (IgE) in serum or plasma. For anemia, it offers ATHOZYME Ferritin, which is an enzyme-immunoassay (ELISA) test for the detection and quantification of Ferritin in human serum. It offers a range of products for Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Antiphospholipid Syndrome (APS), Connective Tissue Disease, Gastrointestinal, and Vasculitis and Renal Disease. Its Fertility Hormones products include PATHOZYME-LH (Luteinizing Hormone), PATHOZYME-Prolactin and PATHOZYME-Oestradiol.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.